Epithalamin

At Verified Peptides, we want to lead with the key classification fact about Epithalamin: it is not a single peptide. It is a natural, multi-component polypeptide extract derived from bovine pineal gland tissue, developed by Prof. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology and registered as a pharmaceutical preparation in Russia, among a small number of Khavinson-developed bioregulator products to achieve formal Russian drug registration.

Epithalamin is the direct natural-extract predecessor to Epithalon (also spelled Epitalon), the single, defined-sequence synthetic tetrapeptide (Ala-Glu-Asp-Gly, AEDG) built elsewhere on this site — the same "cytomax-to-cytogen" relationship documented for other pairs in this catalog, such as Cortexin and Cortagen, or Thymalin and Vilon/Thymogen. Epithalon was specifically synthesized to reproduce, in a single defined molecule, what Khavinson's group identified as the principal active fragment within Epithalamin's more complex natural mixture.

Because Epithalamin is a heterogeneous natural extract rather than one molecule, it cannot be assigned a single molecular formula, molecular weight, or CAS number the way Epithalon can — we are not fabricating small-molecule-style identifiers for a compound that is, by its nature, a mixture. Preclinical comparisons cited in secondary literature suggest Epithalon may match or exceed Epithalamin's biological activity at substantially lower doses (reportedly around 1,000-fold lower in some antioxidant assays), though the authors of these comparisons note that because Epithalamin is a mixture, it remains difficult to determine precisely which of its effects are attributable to the same active fragment Epithalon reproduces versus other components present in the natural extract.

The pineal gland itself, the source tissue for Epithalamin, is an independently well-characterized endocrine structure responsible for synthesizing and secreting melatonin, the primary hormone governing circadian rhythm regulation in mammals, including humans. Pineal gland calcification and reduced melatonin output are well-documented, independently studied features of normal human aging, providing a legitimate scientific rationale for why researchers have long been interested in pineal-derived compounds as potential geroprotector (anti-aging) research tools — a rationale that predates and is independent of Khavinson's own specific extraction and characterization work on Epithalamin.

At Verified Peptides, we think Epithalamin has one of the largest and longest-running human datasets of any compound in this entire catalog, and we want to describe it in full, including its real methodological limitations. The key study (Khavinson and Morozov, "Peptides of pineal gland and thymus prolong human life," Neuro Endocrinol Lett, 2003, PMID 14523363) followed 266 elderly and older patients over 6-8 years, conducted jointly by the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences. Bioregulators (Epithalamin, Thymalin, or both) were administered during the first 2-3 years of observation, with mortality and disease incidence tracked over the full follow-up period.

The reported results were substantial: Epithalamin-treated patients showed a 1.6-1.8-fold reduction in mortality compared to controls; Thymalin-treated patients showed a 2.0-2.1-fold reduction; patients receiving both compounds together showed a 2.5-fold reduction; and patients receiving combined annual re-administration over 6 years showed a 4.1-fold reduction in mortality relative to control. The researchers also reported reduced incidence of respiratory infections, heart disease, hypertension, and osteoarthritis in treated groups, and attributed these improvements to normalized cardiovascular, endocrine, immune, and nervous system function.

We want to be direct about this study's real methodological character: it was a prospective longitudinal cohort study, not a randomized, placebo-controlled, double-blind trial. This is a meaningfully different, generally lower tier of evidence than a true RCT — cohort studies are more susceptible to confounding (patients who received treatment may have differed systematically from controls in ways affecting mortality independent of the peptide treatment itself) and to the specific biases and lack of blinding this design entails. That said, we think a 266-patient, 6-8 year longitudinal human dataset is still a substantially larger and longer human evidence base than exists for almost any other Khavinson-associated compound in this catalog, and represents genuine, real-world longitudinal data rather than a small preclinical study.

No FDA, EMA, or other Western regulatory body has evaluated or approved Epithalamin for any indication, though it is reported to be a registered pharmaceutical product in Russia. At Verified Peptides, we sell research-grade Epithalamin exclusively for laboratory research, and we think its combination of a genuinely large, long-duration human cohort dataset and its structural limitation as a non-single-molecule natural extract makes it one of the more evidentially substantial, if methodologically imperfect, compounds in this entire catalog.

Epithalamin is one of only a small number of Khavinson-developed bioregulator preparations to achieve formal pharmaceutical registration in Russia, a regulatory milestone that most other compounds in this catalog's Khavinson-associated family (including many single-sequence synthetic cytogens) have not reached, despite those compounds sometimes having more extensive laboratory characterization.

The 266-patient mortality cohort study is notable for involving a genuine international collaboration between two research institutions in different countries (St. Petersburg, Russia, and the Institute of Gerontology in Ukraine), rather than being confined to a single institute's own patient population — a meaningfully broader research base than the single-institute pattern seen for most other Khavinson-associated compounds in this catalog, even though it remains within the same overall Khavinson research network rather than fully independent of it.

Separately from the human mortality study, related preclinical research by Anisimov and colleagues examined Epithalon (the synthetic tetrapeptide derived from Epithalamin) in the context of spontaneous tumor incidence and lifespan in rodent models, and a broader review placed both Epithalamin and Epithalon within the context of pineal-axis compounds (alongside melatonin itself) studied for potential inhibitory effects on mammary carcinogenesis — an important, if still preclinical, cancer-relevant research thread connected to this broader family of pineal-derived compounds.

Because Epithalamin is a natural extract rather than a single molecule, batch-to-batch compositional consistency is a more significant practical consideration for this compound than for single-sequence synthetic peptides — researchers relying on precise, reproducible dosing of a specific active component should consider whether Epithalon, the defined synthetic counterpart, may better serve experimental designs requiring exact compositional control.

At Verified Peptides, we require documentation of manufacturing and quality-control standards for research-grade Epithalamin we offer, since it is a natural, standardized biological extract rather than a synthesized single compound. Because Epithalamin is inherently a heterogeneous mixture of peptide fragments rather than one defined molecule, standard single-compound purity metrics such as HPLC purity percentage against one target molecular weight do not directly apply the way they do for a synthesized peptide like Epithalon.

We source exclusively from manufacturers operating under quality-controlled extraction and standardization systems, and we recommend researchers request whatever batch documentation is available and treat any specific compositional consistency claims with appropriate caution given the inherent complexity of fully characterizing a heterogeneous natural peptide-extract mixture compared to a single defined-sequence compound.

Lyophilized Epithalamin should be stored at -20°C, protected from light and moisture, consistent with standard storage guidance for lyophilized natural peptide-extract preparations generally. At Verified Peptides, we ship material with appropriate cold-chain packaging to preserve stability in transit.

Because Epithalamin is a complex mixture of peptide fragments rather than a single molecular species, its overall stability profile reflects the combined behavior of many different components rather than one well-characterized degradation pathway. Researchers should follow the specific storage guidance provided with each lot's documentation and avoid exposure to excessive heat, humidity, or direct light.